SCHEMBL3764374

SCHEMBL3764374

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Br)c(Nc2ccc3[nH]ncc3c2)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 5/20 0.75
▸ PDGFRA P16234 5/20 0.75
▸ EGFR P00533 3/20 0.67
▸ ALK Q9UM73 13/20 0.63
▸ IGF1R P08069 11/20 0.63
▸ INSR P06213 10/20 0.63
▸ FGFR1 P11362 3/20 0.58
▸ PLK1 P53350 2/20 0.57
▸ CHEK1 O14757 2/20 0.56
▸ AURKA O14965 2/20 0.56
▸ JAK2 O60674 2/20 0.56
▸ PRKD3 O94806 2/20 0.56
▸ ABL1 P00519 2/20 0.56
▸ LCK P06239 2/20 0.56
▸ FYN P06241 2/20 0.56
▸ CSF1R P07333 2/20 0.56
▸ RET P07949 2/20 0.56
▸ MET P08581 2/20 0.56
▸ LTK P29376 2/20 0.56
▸ KDR P35968 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766658 0.87 PLK1 (0.62) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL26089299 0.86 ALK (0.83) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL26395575 0.86 PDGFRB (1.00) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL29793855 0.86 PDGFRB (1.00) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL3715939 0.85 EGFR (0.67) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL3716547 0.84 ALK (0.65) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL3717853 0.82 ALK (0.65) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL3793705 0.81 PDGFRB (0.63) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL3714778 0.81 ALK (0.66) PDGFRBPDGFRAEGFRALKIGF1R
SCHEMBL22027940 0.79 EGFR (0.81) EGFRALKIGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435422-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-12-17 — — EP claimed
US-8486933-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-07-16 — — US claimed
US-20100305112-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — US claimed
EP-2435422-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-12-17 — — EP disclosed
US-8486933-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-07-16 — — US disclosed
WO-2010138578-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — WO disclosed
US-20100305112-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305112-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 PDGFRB 174/4885PDGFRA 210/4885EGFR 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback